SEC Form 4 · accession 0001144204-16-096365
Akari Therapeutics Plc · AKTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Byrne
Director
Period of report
Apr 22, 2016
Accepted (ET)
Apr 26, 2016 · 4:31 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001541157
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Options to Purchase Ordinary SharesF1 | $17.96 | Apr 22, 2016 | A | 1,300,000 | A | Apr 22, 2017 | Apr 22, 2026 | Ordinary Shares | 1,300,000 | 1,300,000 | D |
Explanation of responses
- F1All shares underlying the options will vest in three equal annual installments beginning on April 22, 2017, and expire ten years from issuance.